Sangamo BioSciences | SGMO - Current Assets


Sangamo BioSciences reported $49.89M in Current Assets for its fiscal quarter ending in June of 2025.





Current Assets Change Date
Alaunos Therapeutics USD 970K 1.02M Mar/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Alterity Therapeutics Limited AUD 37.91M 15.92M Dec/2025
Amgen USD 34.96B 3.49B Jun/2026
Bayer EUR 33.64B 1.66B Jun/2026
BioCryst Pharmaceuticals USD 484.68M 111.06M Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 3.97B 633.45M Jun/2026
Cipla INR 241.47B 7.71B Mar/2026
Clal Biotechnology ILS 14.69M 1.95M Dec/2023
Compugen USD 137.28M 10.74M Mar/2026
CSL USD 11.85B 1000K Dec/2025
Gilead Sciences USD 12.53B 6.11B Jun/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Grifols EUR 5.96B 316.31M Dec/2025
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
J&J USD 59.77B 601M Jun/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Merck USD 36.68B 1.66B Jun/2026
Novartis USD 27.35B 744M Jun/2026
Omeros USD 69.65M 26.53M Jun/2025
Pfizer USD 41.36B 1.46B Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 31.52B 1.36B Jun/2026
Sarepta Therapeutics USD 2.22B 86.05M Jun/2026
Tectonic Therapeutic USD 239.89M 17.47M Mar/2026
Ultragenyx Pharmaceutical USD 606M 51M Jun/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026